Sosei Group Corporation Announces Operational Activities and Consolidated Results for 2023
Sosei Group Corporation recently announced its operational activities and consolidated results for the year ended December 31, 2023. The biopharmaceutical company, known for its GPCR-targeted StaR® technology and structure-based drug design, received a significant boost with an investment of approximately JPY 8 billion (~USD 54 million) from the new OPF1 fund operated by JIC Venture Growth Investments Co., Ltd. This injection of funds, combined with a share offering and convertible bond restructuring, will fuel the company’s strategic growth, extend its debt maturity profile, and strengthen its financial foundation.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
